Evidence map›Paper›PMID 37715013›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2023

Prognostic Analysis of Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: a Propensity Score-Matched Analysis.

Lei Liu, Longbo Zheng, Shanglong Liu, Maoshen Zhang, Simeng Zhang, Zinian Jiang, Chen Qin, Dongsheng Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Intraperitoneal chemotherapy for gastric cancer.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lei LiuDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Longbo ZhengDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Shanglong LiuDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Maoshen ZhangDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Simeng ZhangDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Zinian JiangDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Chen QinDepartment of Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, 266042, China. qinchen12345@126.com.
Dongsheng WangDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China. wangdongsheng@qdu.edu.cn.
Affiliated Hospital of Qingdao University · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the efficacy of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer (AGC).

methodsWe included 198 patients treated from December 2016 to January 2019; of these patients, the 132 who had clinical T4 gastric cancer were divided into a hyperthermic intraperitoneal chemotherapy group (HIPEC group) and a radical gastrectomy and D2 lymph node dissection group (control group). Because this study was retrospective, we used propensity score matching (PSM) to reduce selectivity bias; we then assessed risk factors for recurrence and compared prognosis in terms of survival in the gastrectomy and prophylactic HIPEC groups.

resultsProphylactic HIPEC reduced the risk of postoperative peritoneal metastasis (PM: 27.5% vs. 10.5%, P = 0.015) and did not increase the risk of postoperative complications, but there was no significant difference in the effect on hepatic metastases or other distant metastases. Risk factors for recurrence included pT4 staging and positive lymph node metastases. Both disease-free survival (DFS: HR 0.592; 95% CI 0.354-0.990; P = 0.042) and peritoneal recurrence-free survival (PFS: HR 0.314; 95% CI 0.127-0.774; P = 0.008) were better in the prophylactic HIPEC group than in the gastrectomy-only group. In addition, there was no difference in the prognosis of patients between the two groups of raltitrexed (RT) and paclitaxel (PTX) for perfusion dosing.

conclusionOur study showed that prophylactic HIPEC could prevent postoperative PM in patients with AGC and did not increase the incidence of postoperative complications. However, it was not found to be effective in the prevention of other metastases, such as hepatic metastases.

Indexed as

Hyperthermia, InducedLiver NeoplasmsStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCytoreduction Surgical ProceduresHumansHyperthermic Intraperitoneal ChemotherapyPostoperative ComplicationsPrognosisPropensity ScoreRetrospective StudiesSurvival RatePeritoneal metastasisProphylactic HIPECT4 gastric cancer

Identifiers

PMID37715013
OpenAlexW4386764835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.